Sweden’s Orexo Forms Partnership With Shanghai’s NovaMed To Enter Chinese Oncology Market
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Swedish pharmaceutical firm Orexo has signed an agreement with Shanghai-based NovaMed for the distribution of Orexo's cancer pain treatment Abstral (fast-dissolving fentanyl) in China